Lung CancerLUCATNCT02493114
Physical Functioning Throughout Lung Cancer Treatment
An observational study of Lung Cancer and Exercise Capacity, run by Hasselt University at 1 site in Belgium.
Trial summary
This trial investigates the impact of lung cancer treatment on physical status, symptoms and quality of life. Furthermore this trial investigates possible underlying causes and consequences of deconditioning. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer, Exercise Capacity, Physical Activity
- How many people
- 150 participants
- Where
- 1 siteBelgium
- Study dates
- Jul 2015to 31 Oct 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Consecutive patients with a primary diagnosis of non-small-cell lung cancer who will undergo treatment (surgery, chemotherapy, immunotherapy, radiotherapy, and combination of the previous ones) and score a maximal of 2 on the WHO performance status classification, will be eligible for inclusion. Healthy matched volunteers will carry out the same assessments once.
Who may be able to join
- undergoing treatment (surgery, chemotherapy, immunotherapy, radiotherapy, and combination of the previous ones)
- WHO performance status of maximal 2
Who cannot join
- presence of other neoplasms in the last 2 years
- bone metastasis
- progressive neuromuscular and neurological diseases
- unstable cardiac disease
- pulmonary hypertension
- interstitial lung disease
Show all 11Show fewer
- orthopedic conditions that significantly impair functional status
- mental or psychiatric disorders that impair the ability to comply with study procedures.
- a history of cerebrovascular accident with remaining functional consequences
- a history of lung cancer
- difficulties in understanding and speaking Dutch
Trial locations and contacts
1 site in 1 country.
About this study
This trial investigates the impact of lung cancer treatment on physical status, symptoms and quality of life. Furthermore this trial investigates possible underlying causes and consequences of deconditioning.
Read the detailed description
Preliminary evidence suggests that patients with lung cancer experience a decrease of exercise tolerance and muscle strength during the course of their treatment. The underlying mechanisms and impact of this change has not yet been investigated. In light of this, our trial will prospectively follow a convenience sample of 150 patients with lung cancer who are undergoing treatment. Patients will be assessed before, during and at the end of the treatment (surgery and/or chemotherapy and/or radiotherapy and/or immunotherapy). The aims of the study are to
- Investigate physical status, before start of treatment in lung cancer patients in comparison with healthy controls (primary outcome).
- Investigate changes in physical status over the course of treatment in lung cancer patients (primary outcome).
- Investigate the relationship between changes in physical status with physical activity and symptoms during treatment for lung cancer (secondary outcome).
- Investigate the relationship between physical status after treatment for lung cancer and comorbidities, hospitalizations and cancer-related and all-cause mortality (exploratory outcome).
- Conditions
- Lung Cancer, Exercise Capacity, Physical Activity, Quality of Life
- Medical subject headings
- Lung Neoplasms, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with lung cancer | No study intervention | |
| Healthy controls | No study intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
6MWT
Measured: Before start of treatment versus 3 months after treatment initiation
1-minute sit to stand test
Measured: Before start of treatment versus 3 months after treatment initiation
SPPB
Measured: Before start of treatment versus 3 months after treatment initiation
Secondary outcomes (4)
Handgrip strength
Measured: Before start of treatment vs. 3 months after treatment initiation
Daily physical activity (self-reported and accelerometer)
Measured: Before start of treatment vs. during treatment (surgery: during hospitalization; radio: week 2; chemo: beginning of cycle 2 and cycle 4 (each cycle is 3 weeks); immuno: beginning of cycle 2 and cycle 4) vs. 3 months after treatment initiation
Quadriceps strength (isometric and isokinetic)
Measured: Before start of treatment vs. 3 months after treatment initiation
Respiratory muscle strength (maximal inspiratory and expiratory pressure)
Measured: Before start of treatment vs. 3 months after treatment initiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2015 (estimated)
- Study startJul 2015
- Primary completion31 Oct 2024
- Study completion31 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hasselt University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chris Burtin, Hasselt University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02493114
- Sponsor's protocol ID
- 1
- Acronym
- LUCAT
- Status last verified
- Sep 2025
- First submitted
- 11 Jun 2015
- Last updated
- 15 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
Publications
Quadflieg K, Arents E, Haesevoets S, Van Hulle F, Hermans F, Criel M, Daenen M, Derom E, Spruit MA, Surmont V, Stevens D, Ruttens D, Demeyer H, Burtin C. Impact of cancer treatment on physical functioning, symptoms and health-related quality of life in patients with non-small cell lung cancer: A longitudinal observational study. Respir Med. 2025 Oct;247:108283. doi: 10.1016/j.rmed.2025.108283. Epub 2025 Jul 31.
PubMed 40752628
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Physical Functioning Throughout Lung Cancer Treatment
- ClinicalTrials.gov ID
- NCT02493114
- Acronym / sponsor ID
- LUCAT / 1
- Conditions
- Lung Cancer, Exercise Capacity, Physical Activity, Quality of Life
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Hasselt UniversityUniversity, hospital or other
- Study start
- Jul 2015
- Primary completion
- 31 Oct 2024 (actual)
- Study completion
- 31 Oct 2024 (actual)
- First posted
- 9 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial investigates the impact of lung cancer treatment on physical status, symptoms and quality of life. Furthermore this trial investigates possible underlying causes and consequences of deconditioning.
Detailed description
Preliminary evidence suggests that patients with lung cancer experience a decrease of exercise tolerance and muscle strength during the course of their treatment. The underlying mechanisms and impact of this change has not yet been investigated. In light of this, our trial will prospectively follow a convenience sample of 150 patients with lung cancer who are undergoing treatment. Patients will be assessed before, during and at the end of the treatment (surgery and/or chemotherapy and/or radiotherapy and/or immunotherapy). The aims of the study are to
- Investigate physical status, before start of treatment in lung cancer patients in comparison with healthy controls (primary outcome).
- Investigate changes in physical status over the course of treatment in lung cancer patients (primary outcome).
- Investigate the relationship between changes in physical status with physical activity and symptoms during treatment for lung cancer (secondary outcome).
- Investigate the relationship between physical status after treatment for lung cancer and comorbidities, hospitalizations and cancer-related and all-cause mortality (exploratory outcome).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with lung cancer | – | –No study intervention |
| Healthy controls | – | –No study intervention |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Consecutive patients with a primary diagnosis of non-small-cell lung cancer who will undergo treatment (surgery, chemotherapy, immunotherapy, radiotherapy, and combination of the previous ones) and score a maximal of 2 on the WHO performance status classification, will be eligible for inclusion. Healthy matched volunteers will carry out the same assessments once.
Key inclusion criteria (2 listed)
- undergoing treatment (surgery, chemotherapy, immunotherapy, radiotherapy, and combination of the previous ones)
- WHO performance status of maximal 2
Key exclusion criteria (11 listed)
- presence of other neoplasms in the last 2 years
- bone metastasis
- progressive neuromuscular and neurological diseases
- unstable cardiac disease
- pulmonary hypertension
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
6MWT
Time frame: Before start of treatment versus 3 months after treatment initiation
1-minute sit to stand test
Time frame: Before start of treatment versus 3 months after treatment initiation
SPPB
Time frame: Before start of treatment versus 3 months after treatment initiation
4 secondary outcomes
Handgrip strength
Time frame: Before start of treatment vs. 3 months after treatment initiation
Daily physical activity (self-reported and accelerometer)
Time frame: Before start of treatment vs. during treatment (surgery: during hospitalization; radio: week 2; chemo: beginning of cycle 2 and cycle 4 (each cycle is 3 weeks); immuno: beginning of cycle 2 and cycle 4) vs. 3 months after treatment initiation
Quadriceps strength (isometric and isokinetic)
Time frame: Before start of treatment vs. 3 months after treatment initiation
Respiratory muscle strength (maximal inspiratory and expiratory pressure)
Time frame: Before start of treatment vs. 3 months after treatment initiation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2025.
- Derived from this study: PubMed 40752628Quadflieg K, Arents E, Haesevoets S, Van Hulle F, Hermans F, Criel M, Daenen M, Derom E, Spruit MA, Surmont V, Stevens D, Ruttens D, Demeyer H, Burtin C. Impact of cancer treatment on physical functioning, symptoms and health-related quality of life in patients with non-small cell lung cancer: A longitudinal observational study. Respir Med. 2025 Oct;247:108283. doi: 10.1016/j.rmed.2025.108283. Epub 2025 Jul 31.
Related trials for Lung Cancer
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Not yet recruitingPhase 3
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
RecruitingObservational study
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Lung Cancer
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer and Exercise Capacity, run by Hasselt University at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
6MWT (time frame: Before start of treatment versus 3 months after treatment initiation). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02493114, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2025.